Clinical Trial Update: A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing eribulin mesylate versus ixabepilone in causing or worsening neuropathy in advanced breast cancer; results completed with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• Ixabepilone (ixabepilone)

Snippet

Sponsor: Eisai Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-12-01